Results from clinical studies with small molecule inhibitors of mutant B-RAF have been very encouraging in the treatment of melanoma, but frequent recurrence of tumor growth following initial remission remains a major obstacle for more successful treatment of the disease. We show in this report that B-RAF V600E melanoma cells selected for resistance to apoptosis induced by the RAF inhibitor PLX4720 by prolonged exposure to the inhibitor can proliferate even in the presence of the inhibitor. Survival of these cells is primarily mediated by activation of ERK that is largely independent of the conventional RAF/MEK/ERK pathway.
Introduction
Results from clinical studies with small molecule inhibitors of the mutant B-RAF V600E have been very encouraging and promise to provide a much needed breakthrough in the treatment of melanoma by targeting B-RAF V600E (1, 2) . The latter is found in about 50% of melanomas leading to constitutive activation of the RAF/MEK/ERK pathway that is important for melanoma cell growth and survival, and is involved in resistance to many therapeutic agents (3, 4) . However, a number of questions have already been raised from these studies, such as the durability of responses and why some melanomas with mutant B-RAF have not shown major responses.
It is well-established that blockade of the RAF/MEK/ERK pathway inhibits melanoma cell growth (5) . Moreover, induction of apoptosis has also been shown in varying in-vitro systems, in particular, in B-RAF V600E melanoma cells (6) (7) (8) (9) (10) (11) . Apoptosis of such cells was clearly demonstrated in an ex-vivo model after administration of the B-RAF inhibitor PLX4720 that is selective for the mutant B-RAF V600E (6) . Consistently, regression of metastatic mutant B-RAF melanomas is a frequent sign of the response to administration of PLX4032/ RG7204, an analogue to PLX4720, suggesting that induction of apoptosis may be a major biological consequence of inhibition of mutant B-RAF that causes remission of melanoma (1, 2) .
Although molecular mechanisms that regulate sensitivity of B-RAF V600E melanoma cells to apoptosis induced by specific inhibitors are currently not well understood, it has been reported that acquired resistance of melanoma cells to the inhibitors was associated with rebound activation of the RAF/MEK/ERK pathway (12, 13) . Signaling to activate MEK/ERK has been shown to switch to C-RAF when mutant B-RAF was inhibited due to elevated C-RAF expression (12) . Moreover, most melanoma cells harboring the B-RAF followed by the desired treatment. Cells were then labeled with the VisionBlue TM reagent and detected by Synergy TM 2 multi-detection microplate reader (BioTek, VT) according to the manufacturer's instruction.
Flow Cytometry
Immunostaining on intact and permeabilized cells was carried out as described previously (20, 21) .
Western Blot analysis
Western blot analysis was carried out as described previously (20, 21 (20) . In addition, it is conceivably relevant to applications in vivo, as plasma concentrations of a closely related inhibitor PLX4032/RG7204 of around 60μM were not associated with significant adverse effects in phase I clinical trials (1, 22) . As expected, initial exposure to PLX4720 at 10μM for 3 days induced apoptosis in more than 60% of Mel-RMu and Mel-CV cells. However, the levels of apoptosis in the remaining cells exposed to fresh PLX4720 decreased progressively ( Figure   1A ). At the end of three weeks, the levels of apoptosis of the cells in the presence of PLX4720 were equivalent to those of the parental counterparts without any treatment (≤5%), indicative of successful selection of B-RAF V600E melanoma cells resistant to apoptosis induced by PLX4720 ( Figure 1A ). For standardization, only the cells that had been exposed to PLX4720 for at least twenty weeks were designated as PLX-selected cells and used for subsequent experiments. Notably, both PLX-selected Mel-RMu (Mel-RMu.S) and Mel-CV (Mel-CV.S) cells retained the V600E mutation in B-RAF, whereas Mel-CV.S cells also retained the activating mutation in EGFR (data not shown).
Despite resistance to apoptosis, the PLX-selected cells proliferated significantly slower than their parental counterparts ( Figure 1B) . Consistently, the cells displayed increased levels of p21 and p27, and decreased levels of cyclin D1 and CDK4 ( Figure 1C ). Nevertheless, these
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PLX-Selected B-RAF V600E Melanoma Cells Exhibit High Levels of ERK Activation that is largely Independent of MEK
As reported before, initial exposure to PLX4720 at 10μM resulted in marked inhibition of ERK activation, with the inhibitory effect sustained up to 3 days in Mel-RMu and Mel-CV cells (20) (Figure 2A ). However, activation of ERK in the remaining cells was steadily recovered in the presence of fresh PLX4720. By 9 days, the levels of ERK activation were comparable to those in cells without exposure to PLX4720 (Figure 2A) . Notably, the levels appeared even higher in the PLX-selected cells (the cells that had been exposed to PLX4720
for at least 20 weeks) than their parental counterparts. We studied whether signaling to activate ERK was switched to C-RAF in the PLX-selected cells. As shown in Figure 2D , the levels of C-RAF in Mel-RMu.S and Mel-CV.S cells were increased in comparison with their parental counterparts. However, inhibition of C-RAF by siRNA did not reduce the levels of ERK activation in the PLX-selected cells, nor did it inhibit activation of ERK in the parental counterparts. These results suggest that the increase in C-RAF in B-RAF V600E melanoma cells after prolonged inhibition of B-RAF V600E may not be responsible for rebound activation of ERK.
Activation of ERK Contributes to Survival of PLX-Selected Melanoma Cells
We examined the role of activation of ERK in survival of the PLX-selected melanoma cells by transfecting siRNA pools for ERK1 and ERK2 into the Mel-RMu.S and Mel-CV.S cells, respectively ( Figure 3A ). As shown in Figure 3B , inhibition of ERK1 or ERK2 by siRNA induced moderate levels of apoptosis (25%-35%) in both lines. This was associated with activation of caspase-3 ( Figure 3C ). In contrast, siRNA knockdown of ERK1 or ERK2 did We also examined the effect of inhibition of the PI3k/Akt pathway on survival of the PLX4720-selected B-RAF V600E melanoma cells. As shown in Figure 6B , the addition of the
Discussion
The above results show that B-RAF V600E melanoma cells selected for resistance to apoptosis induced by PLX4720 can proliferate, albeit with reduced growth rate, in the presence of the inhibitor. Survival of these cells is associated with rebound activation of ERK that is largely independent of the conventional RAF/MEK/ERK pathway. Instead, elevated activation of the PI3k/Akt pathway as a result of extracellular stimulation appears to be important. The results suggest that melanoma recurrence in patients treated with selective mutant B-RAF inhibitors may not respond to MEK inhibitors, but may be susceptible to inhibitors against the PI3k/Akt pathway.
Although the RAF/MEK/ERK pathway was initially thought to be mainly responsible for regulation of cell proliferation (27, 28) , it is now clear that this pathway also plays an important role in regulation of cell survival (27, 28) . Blockade of this pathway can cause not only inhibition of cell growth but also induction of apoptosis in melanoma cells (6) (7) (8) (9) . Mutant B-RAF-specific inhibitors display the dual effects on B-RAF V600E melanoma cells, but the relative contributions of inhibition of cell growth and induction of apoptosis to the therapeutic effect remain ambiguous (6, 13) . Despite the high rate of clinical responses in patients treated with mutant B-RAF-specific inhibitors such as PLX4032/RG7204 and GSK2118436, longer follow-up has shown frequent recurrence of tumor growth (13, 30) . It is conceivable that induction of apoptosis may occur at early stages after inhibition of mutant B-RAF, but the remaining cells that are presumably resistant to apoptosis may retain low proliferation potential even in the presence of the inhibitors, and regain high growth rate after the inhibition is removed. In corroboration with this, we found in this study that although initial exposure to PLX4720 induced apoptosis in most melanoma cells harboring B-RAF V600E , the remaining cells could proliferate, albeit with slow growth rate, even in the presence of a relatively high concentration of the inhibitor for prolonged periods. These results highlight
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